 Connection
Ping-Ching Hsu to Anti-Bacterial Agents
This is a "connection" page, showing publications Ping-Ching Hsu has written about Anti-Bacterial Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.116 |
|
|
|
-
Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Chen YH, Tsai TJ, Wu DC, Tsai KW. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. J Gastroenterol Hepatol. 2019 Nov; 34(11):1968-1976.
Score: 0.402
-
Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018 Aug; 23(4):e12498.
Score: 0.373
-
Chuah YY, Wu DC, Chuah SK, Yang JC, Lee TH, Yeh HZ, Chen CL, Liu YH, Hsu PI. Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey). Helicobacter. 2017 Jun; 22(3).
Score: 0.341
-
Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014 Oct; 58(10):5936-42.
Score: 0.285
-
Wu PJ, Tsay FW, Wu DC, Yang JC, Chuah SK, Chen KY, Chen CL, Lee CL, Shih CA, Liu YH, Shiu SI, Tai WC, Kuo CH, Lei WY, Kao SS, Tsai TJ, Feng IC, Koseki M, Hsu PI, Sheu MJ. Sequential changes of antibiotic resistances of Helicobacter pylori in Taiwan from 2019 to 2024. World J Gastroenterol. 2025 Oct 21; 31(39):111380.
Score: 0.155
-
Hsu PI, Chen KY, Tai WC, Yang JC, Tsay FW, Liu YH, Chen CL, Lee CL, Yeh HZ, Kuo CH, Chuah SK, Lee HC, Shie CB, Shiu SI, Kao JY, Yamaoka Y, Graham DY, Wu DC. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
Score: 0.130
-
Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter. 2021 Oct; 26(5):e12840.
Score: 0.116
-
Wang JW, Hsu CN, Tai WC, Ku MK, Hung TH, Tseng KL, Yuan LT, Nguang SH, Liang CM, Yang SC, Wu CK, Hsu PI, Wu DC, Chuah SK. The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer Diseases. PLoS One. 2016; 11(10):e0164824.
Score: 0.083
-
Chen TA, Tsao YC, Chen A, Lo GH, Lin CK, Yu HC, Cheng LC, Hsu PI, Tsai WL. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol. 2009; 44(5):619-25.
Score: 0.048
-
Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, Tsay FW, Wu CJ, Lo CC, Tseng HH, Yamaoka Y, Chen JL, Lo GH. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005 Nov; 100(11):2387-92.
Score: 0.039
-
Chuah YY, Wu DC, Chuah SK, Chen KY, Yang JC, Lee CL, Chen CL, Shiu SI, Shie CB, Shih CA, Tsay FW, Liu YH, Hsu PI. REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020. Helicobacter. 2022 Dec; 27(6):e12931.
Score: 0.031
-
Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020 09; 7(1).
Score: 0.027
-
Tsai HJ, Tai JJ, Chen LT, Wu MS, Yeh KH, Lin CW, Wang TE, Wang HP, Yu FJ, Liou JM, Hsiao CF, Cheng TY, Yeh HJ, Ko CW, Chen MJ, Lo GH, Hsu PI, Chang CS, Hwang WS, Chuang SS, Lee HW, Shun CT, Chiu CF, Wang WM, Hsieh CY, Liu TW, Lin JT, Kuo SH, Cheng AL. A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. Haematologica. 2020 07; 105(7):e349-e354.
Score: 0.026
-
Kuo SH, Chen LT, Lin CW, Yeh KH, Shun CT, Tzeng YS, Liou JM, Wu MS, Hsu PN, Cheng AL. Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. Blood. 2017 01 12; 129(2):188-198.
Score: 0.021
-
Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother. 2013 Jan; 68(1):222-8.
Score: 0.016
-
Wu DC, Hsu PI, Tseng HH, Tsay FW, Lai KH, Kuo CH, Wang SW, Chen A. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore). 2011 May; 90(3):180-185.
Score: 0.014
-
Wu CJ, Hsu PI, Lo GH, Lo CC, Lin CK, Shie CB, Peng NJ, Tseng HH, Jou HS, Tsai PM, Chen A, Chen JL, Lai KH. Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection. J Chin Med Assoc. 2004 Apr; 67(4):161-7.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|